Study identifier:RDEA3170-107
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase 1b, Randomized, Open-label Study to Evaluate the Potential Pharmacokinetic and Pharmacodynamic Interactions Between RDEA3170 and Allopurinol in Adult Male Subjects with Gout
Gout
Phase 1
No
RDEA3170 10 mg, allopurinol 300 mg
Male
12
Interventional
18 Years - 75 Years
Allocation: Randomized
Endpoint Classification: Pharmacokinetics/dynamics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Basic Science
Verified 01 Sept 2015 by Ardea Biosciences, Inc.
Ardea Biosciences, Inc.
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Sequence A RDEA3170 qd (once daily), RDEA3170 + allopurinol qd, allopurinol qd | - |
Experimental: Sequence B allopurinol qd, RDEA3170 + allopurinol qd, RDEA3170 qd | - |